Travere Therapeutics stock
TVTXNASDAQTravere Therapeutics, Inc., HealthcareISIN US89422G1076
50Score 50 out of 100, Neutral
Price and trend
72 / 100
Price history
+41% in one yearThe chart shows daily closes over 14 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 8.3% above it.
Since September 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 56).
The price is 24% below its 52-week high. Largest decline in 14 years: 85% (August 2015 to April 2024).
Chart figures for advanced users
- SMA 50$56.25
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$47.59
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)56
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$26.79
- The lowest closing price of the last twelve months.
- Resistance$67.52
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Travere Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $4.95B, is number 75 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $490.73M (up 110.5% year on year) and a loss of $25.55M.
- For fiscal 2026, analysts expect on average revenue of $768.82M (up 56.7%) and adjusted earnings per share of −$0.79.
Show more
- MEQIRI Score 50 out of 100 (Neutral): rank 380 of 702 in Healthcare, median 53.
- Our model puts fair value at $115.51, with the price 55% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 33.7% a year since 2020, Biotechnology median 19.4%.Growth 70
Weaknesses
- High debtDebt 27.28 times equity (latest quarter), Biotechnology median 0.09.Stability 28
- DilutionShare count up 88% since 2020.Capital allocation 18
- Loss-makingLoss of $121.51M over the last 12 months.Fundamentals 17
Its standout strengths are valuation and momentum, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $77.01 and expensive above $231.03 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 9.7%. At 10.7% the fair value would be $97.86, at 8.7% it would be $140.42.
Possible value trap: looks cheap, but high risk, weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 49.4% on the twelve months before. Up to 2020 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 33.7% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 98%, operating −13%, net not measured.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Feb 2027in 97 days
- Last reported
- 2 Nov 2026EPS reported −$0.55 (expected −$0.06)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 2,488.9% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.79−2,488.9%
- Revenue
- $768.82M+6.1%
- Earnings per share
- $3.00−5.1%
- Revenue
- $1.15B+6.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +14.2%No numeric guidance; management expects demand for FILSPARI in FSGS and IgA nephropathy to keep growing.
“Travere has now entered a new chapter, one that we expect will deliver near- and long-term growth driven by clear momentum across 4 key pillars: continued growth for FILSPARI in IgA nephropathy, the successful launch of FILSPARI in FSGS, the advancement of pegtibatinase in its pivotal Phase III study and the addition …”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 11 insiders sold, $81M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Dube Eric MSale
15 Oct 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 243,735
- Price
- $53.82
- Value
- $13.12M
- Heerma PeterSale
17 Sept 2026, EVP, CHIEF COMMERCIAL OFFICER
- Shares
- 8,282
- Price
- $65.07
- Value
- $538,917
- Dube Eric MSale
17 Sept 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 108,493
- Price
- $64.61
- Value
- $7.01M
Show 17 more
- Rote William E.Sale
16 Sept 2026, Chief Research Officer
- Shares
- 112,850
- Price
- $63.33
- Value
- $7.15M
- Heerma PeterSale
16 Sept 2026, EVP, CHIEF COMMERCIAL OFFICER
- Shares
- 172,717
- Price
- $63.43
- Value
- $10.96M
- Dube Eric MSale
16 Sept 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 195,841
- Price
- $63.45
- Value
- $12.43M
- Rote William E.Sale
15 Sept 2026, Chief Research Officer
- Shares
- 96,198
- Price
- $62.25
- Value
- $5.99M
- Heerma PeterSale
15 Sept 2026, EVP, CHIEF COMMERCIAL OFFICER
- Shares
- 102,190
- Price
- $62.26
- Value
- $6.36M
- Inrig JulaSale
15 Sept 2026, EVP, Head of R&D & CMO
- Shares
- 44,674
- Price
- $62.34
- Value
- $2.79M
- Reed Elizabeth ESale
15 Sept 2026, Chief Legal Officer and GC
- Shares
- 37,500
- Price
- $62.34
- Value
- $2.34M
- Dube Eric MSale
15 Sept 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 95,666
- Price
- $62.26
- Value
- $5.96M
- Cline Christopher R.Sale
15 Sept 2026, CHIEF FINANCIAL OFFICER
- Shares
- 50,508
- Price
- $62.34
- Value
- $3.15M
- Calvin SandraSale
15 Sept 2026, SVP, CHIEF ACCOUNTING OFFICER
- Shares
- 5,375
- Price
- $62.33
- Value
- $335,005
- Meckler Jeffrey ASale
10 Sept 2026, Board
- Shares
- 20,000
- Price
- $67.31
- Value
- $1.35M
- Cline Christopher R.Sale
2 Sept 2026, CHIEF FINANCIAL OFFICER
- Shares
- 642
- Price
- $66.37
- Value
- $42,610
- Lyons Gary ASale
18 Aug 2026, Board
- Shares
- 5,000
- Price
- $63.37
- Value
- $316,860
- Lyons Gary ASale
17 Aug 2026, Board
- Shares
- 5,000
- Price
- $63.20
- Value
- $315,986
- Coughlin TimothySale
12 Jun 2026, Board
- Shares
- 10,000
- Price
- $50.07
- Value
- $500,747
- Baynes Roy D.Sale
12 Jun 2026, Board
- Shares
- 4,500
- Price
- $50.00
- Value
- $225,000
- Coughlin TimothySale
15 May 2026, Board
- Shares
- 3,250
- Price
- $43.49
- Value
- $141,343
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Travere Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 50
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- PTC TherapeuticsPTCT $5.29B46
- Dianthus TherapeuticsDNTH $5.21B46
- SK Biopharmaceuticals326030.KS $5.14B67
- Cogent BiosciencesCOGT $5.07B28
- Edgewise TherapeuticsEWTX $4.93B54
- Adaptive BiotechnologiesADPT $4.77B47
- Ionis PharmaceuticalsIONS $4.55B32
- Definium TherapeuticsDFTX $4.52B41
ETFs that hold Travere Therapeutics
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 1.99% | 0.49% | €26.29M |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.31% | 0.30% | €185.82M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.30% | 0.35% | €1.25B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.15% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.15% | 0.30% | €2.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.06% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.04% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.04% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026, previously Weak
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.